HONZ(SZ:300086) Zhong Guo Jing Ji Wang·2025-09-11 08:11Core Viewpoint - Kangzhi Pharmaceutical announced a share transfer agreement involving 5.0004% of its shares, indicating a strategic move by its major shareholder to raise funds for other investments while reflecting confidence in the company's future prospects [1][2]. Summary by Sections Share Transfer Details - The controlling shareholder, Hainan Hongshi Investment Co., Ltd., will transfer 22,758,000 shares (5.0004% of total shares) to Beijing Chenle Asset Management Co., Ltd. for a price of 5.34 CNY per share, totaling approximately 121.53 million CNY [1]. - Prior to the transfer, Chenle Jiaxiang No. 4 did not hold any shares in Kangzhi Pharmaceutical, and post-transfer, it will hold 22,758,000 shares, representing 5.0004% of the total share capital [1]. Impact on Shareholder Structure - Before the transfer, Hainan Hongshi held 124,038,747 shares (27.2538% of total shares). After the transfer, it will hold 101,280,747 shares (22.2534%) [2]. - Hainan Hongshi and its concerted parties will collectively hold 120,476,598 shares, accounting for 26.47% of the total share capital [2]. Purpose of the Share Transfer - The share transfer is aimed at raising funds for Hainan Hongshi to fulfill commitments related to the acquisition of 100% equity in Zhongshan Aihu Daily Necessities Co., Ltd. [2]. - The transaction reflects Chenle Asset Management's recognition of Kangzhi Pharmaceutical's future development potential and investment value, as well as its own business development needs [2].